SCHEMBL23479213

SCHEMBL23479213

CC(C)(C)c1ccc2nc(CC(C)(C)c3cc4ccncc4[nH]3)[nH]c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.46
▸ SCN10A Q9Y5Y9 12/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ METAP2 P50579 1/20 0.40
▸ NR3C1 P04150 2/20 0.39
▸ PGR P06401 2/20 0.39
▸ NR3C2 P08235 1/20 0.39
▸ PRKCZ Q05513 1/20 0.37
▸ FGFR1 P11362 2/20 0.36
▸ FLT3 P36888 2/20 0.36
▸ CLK4 Q9HAZ1 2/20 0.36
▸ PLK4 O00444 1/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ AURKA O14965 1/20 0.36
▸ CHUK O15111 1/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ ROCK2 O75116 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ PAK4 O96013 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23478691 0.85 RAD52 (0.36) NR3C1PGRNR3C2
SCHEMBL23479351 0.84 SCN10A (0.40) SCN10ANR3C1PGRNR3C2PRKCZ
SCHEMBL23479517 0.79 PDE10A (0.43) PDE10ASCN10AKCNH2METAP2PRKCZ
SCHEMBL12571647 0.72 DAO (0.49) NR3C1PGRNR3C2CHUKSYK
SCHEMBL12190473 0.72 SCN10A (0.58) PDE10ASCN10AKCNH2METAP2FGFR1
SCHEMBL21022998 0.71 PDE10A (0.46) PDE10ASCN10AKCNH2METAP2PRKCZ
SCHEMBL23376988 0.71 PDE10A (0.60) PDE10ASCN10AKCNH2METAP2PRKCZ
SCHEMBL23453154 0.71 DAO (0.42) NR3C1PGRNR3C2
SCHEMBL20993310 0.71 NR3C1 (0.38) NR3C1PGRNR3C2
SCHEMBL15945343 0.70 SCN10A (0.62) PDE10ASCN10AKCNH2METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-17 — — US disclosed
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 PDE10A 3690/4885SCN10A 4409/4885KCNH2 4493/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 PDE10A 3690/4885SCN10A 4409/4885KCNH2 4493/4885
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 PDE10A 3690/4885SCN10A 4409/4885KCNH2 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback